Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy.
Shah
Manish A
MA
Ilson
David
D
Kelsen
David P
DP
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D006801:Humans; D015994:Incidence; D000077146:Irinotecan; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy*; D013923:Thromboembolism / Q000139:chemically induced* / Q000453:epidemiology*; D019851:Thrombophilia / Q000150:complications* / Q000209:etiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000077146:Irinotecan; D002166:Camptothecin